The World Conference on Lung Cancer (WCLC), a significant academic exchange event in the global lung cancer field, was successfully held in Singapore from September 9 to 12, 2023. The conference revealed many important research findings, bringing about a new era of treatment in clinical practice. Among them, the EGFR Exon20 insertion mutation (EGFR exon20ins) as the third major EGFR mutation has garnered widespread attention. In recent years, novel treatments for this mutation have continuously emerged. At the WCLC, the phase 1b results of the FAVOUR study on the treatment of EGFR exon20ins-positive advanced non-small cell lung cancer (NSCLC) with furmonertinib were reported. " Oncology Frontier " had the privilege of interviewing Dr. Caicun Zhou, a leading figure in the field of lung cancer treatment at Shanghai Pulmonary Hospital and Tongji University School of Medicine. Dr. Zhou shared the latest treatments of EGFR exon20ins-positive NSCLC.
